PARIS: Iktos, a company specialized in Artificial Intelligence for new drug design, announced the appointment of Roman Fleck as Chairman of the Board. Yann Gaston-Mathé steps down of his role as Chairman to focus on his CEO duties.
Roman Fleck holds an MBA from New York University (Sterne School of Business) and received a PhD in organic chemistry from MIT (Massachusetts Institute of Technology), USA.
He began his career as a principal scientist with Boehringer Ingelheim Pharmaceuticals, where he led drug development projects in oncology, inflammation and cardiovascular disease. After that he joined investment firm Index Ventures Life Sciences, which became Medicxi Ventures in 2014. He has notably invested in GlycoVaxyn (sold to GSK), Versartis (NASDQ: VSAS) and Novocure (NASDQ: NVCR). He represented Medicxi Ventures on the boards of these companies.
From 2017 to 2022, he was CEO of Janpix, Ltd, an oncology-focused biotech that became part of Centessa Pharmaceuticals in 2021.
Roman is currently Chairman of HDAX Therapeutics, a biotech focused on CNS (central nervous system), and an Independent Board Member at ReColony, a microbiome focused company.
Roman Fleck, Chairman of the Supervisory Board, comments: “I am delighted to join the Board of Iktos, a pioneering company which has been advancing AI-driven drug discovery since 2016. Since then, Iktos has developed a technology platform which allows it to offer comprehensive drug discovery solutions to its clients that are unique in the industry. I look forward to sharing my insights and supporting Yann & Iktos as it continues to advance its strategy and builds upon its position as a leader in the field.”
Yann Gaston-Mathé, co-founder and CEO of Iktos, comments: “Roman has an exceptional professional background with unvaluable experience in pharmaceutical research, investment and company leadership. We are delighted that he has agreed to chair Iktos’ Board of Directors. His deep understanding of the biotech industry and broad network within the investment and pharma communities will be a strategic advantage for the development of Iktos. At a personal level, I look forward to working closely with Roman and learning from his experience.”